Dueling BRCA Databases: What About the Patient?
The news release Monday morning grabbed my attention:
�Study finds wide gap in quality ofBRCA1/2variant classification between Myriad Genetics and a common public database.�
Myriad Genetics had been exclusively providing the tests, for $3000+ a pop for full BRCA gene sequencing, for 17 years before the Supreme Court invalidated key gene patents back in 2013. Since the ruling a dozen or so competitors have been offering the tests for much lower prices. Meanwhile, Myriad has amassed a far deeper database than anyone else, having been in the business so much longer. And it�s proprietary.
�Study finds wide gap in quality ofBRCA1/2variant classification between Myriad Genetics and a common public database.�
Myriad Genetics had been exclusively providing the tests, for $3000+ a pop for full BRCA gene sequencing, for 17 years before the Supreme Court invalidated key gene patents back in 2013. Since the ruling a dozen or so competitors have been offering the tests for much lower prices. Meanwhile, Myriad has amassed a far deeper database than anyone else, having been in the business so much longer. And it�s proprietary.
No comments have been added yet.
